Chemo Choice May Minimize Toxicity Disparities for Black Patients With Breast Cancer

Among the taxanes currently approved for breast cancer treatment, docetaxel is the preferred agent for Black patients with breast cancer, researchers concluded in study findings presented at the 2024 American Society of Clinical Oncology Annual Meeting. In a study that only enrolled Black patients with breast cancer, the researchers found that docetaxel was associated with the lowest risk for taxane-induced peripheral neuropathy, a dose-limiting adverse event that typically occurs more frequently in Black individuals.